Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-000473-23
    Sponsor's Protocol Code Number:CULM20236
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-07-04
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2019-000473-23
    A.3Full title of the trial
    A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
    Estudio fase 2 de Cusatuzumab más Azacitidina en Pacientes de Nuevo Diagnóstico de Leucemia Mieloide Aguda que no son candidatos a Quimioterapia Intensiva
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Clinical Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy.
    Un estudio clínico de Cusatuzumab más azacitidina en pacientes con leucemia mieloide aguda recién diagnosticada que no son candidatos para quimioterapia intensiva
    A.4.1Sponsor's protocol code numberCULM20236
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorOncoVerity Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportOncoVerity Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationOncoVerity Inc
    B.5.2Functional name of contact pointOncoVerity Help Desk
    B.5.3 Address:
    B.5.3.1Street Address12635 East Montview Blvd., Suite 175
    B.5.3.2Town/ cityAurora colorado
    B.5.3.3Post code2333
    B.5.3.4CountryUnited States
    B.5.6E-mailoncoverityhelpdesk@oncoverity.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/20/2265
    D.3 Description of the IMP
    D.3.1Product nameCusatuzumab
    D.3.2Product code OV-1001
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCUSATUZUMAB
    D.3.9.1CAS number 1864871-20-4
    D.3.9.2Current sponsor codeOV-1001
    D.3.9.4EV Substance CodeSUB195527
    D.3.10 Strength
    D.3.10.1Concentration unit mg/kg milligram(s)/kilogram
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number10 to 20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vidaza
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene US, Celgene BV
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAzacitidine
    D.3.4Pharmaceutical form Powder for suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINE
    D.3.9.1CAS number 320-67-2
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vidaza
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAzacitidine
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINE
    D.3.9.1CAS number 320-67-2
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute Myeloid Leukemia
    Leucemia mieloide aguda
    E.1.1.1Medical condition in easily understood language
    Blood cancer
    cancer en la sangre
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10000886
    E.1.2Term Acute myeloid leukemia
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the efficacy of cusatuzumab in combination with azacitidine in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy
    Determinar la eficacia del cusatuzumab en combinación con azacitidina en pacientes con leucemia mieloide aguda (LMA) no tratada previamente que no son elegibles para la quimioterapia intensiva.
    E.2.2Secondary objectives of the trial
    1) To determine the below responses
    a) Complete response (CR)
    b) CR with incomplete recovery (CRi)
    c) CR with partial hematological revovery (CRh)
    d) CR without MRD (CRMRD-)
    e) Morphologic leukemia-free state (MLFS)
    f) Partial response (PR)
    g) Stable disease
    h) Relapse after CR, CRi, CRh
    i) Progressive Disease
    2) To assess time to response and duration of response
    3)To determine transfusion independence
    4) To assess the safety profile of cusatuzumab in combination with azacitidine
    5) To assess the pharmacokinetics of cusatuzumab alone and in combination with azacitidine
    6) To assess the immunogenicity of cusatuzumab alone and in combination with azacitidine
    1) Determinar las siguientes respuestas
    a) Respuesta completa (RC)
    b) RC con recuperación incompleta (RCi)
    c) RC con recuperación hematológica parcial (RCh)
    d) RC sin MRD (RCMRD-)
    e) Estado morfológico libre de leucemia (MLFS)
    f) Respuesta parcial (RP)
    g) Enfermedad estable
    h) Recaída después de RC, RCi, RCh
    i) Enfermedad Progresiva
    2) Evaluar el tiempo de respuesta y la duración de la respuesta
    3) Para determinar la independencia de la transfusion
    4) Evaluar el perfil de seguridad del cusatuzumab en combinación con azacitidina
    5) Evaluar la farmacocinética del cusatuzumab solo y en combinación con azacitidina.
    6) Evaluar la inmunogenicidad del cusatuzumab solo y en combinación con azacitidina.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Each potential participant must satisfy all of the following criteria to be enrolled in the study:
    1. ≥18 years of age
    2. Criterion modified per Amendment 1
    2.1. AML according to WHO 2016 criteria and fulfilling all of the following criteria that defines those who are “not candidates for intensive chemotherapy”:
    ● ≥75 years of age or
    ● <75 years of age with of at least one of the following comorbidities:
    o Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
    o Severe cardiac comorbidity defined as congestive heart failure or ejection fraction ≤50%
    o Severe pulmonary comorbidity defined as documented pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected, or forced expiratory volume in 1 second (FEV1) ≤65% of expected or dyspnea at rest requiring oxygen
    o Moderate hepatic impairment defined according to National Cancer Institute (NCI) organ dysfunction classification criteria (total bilirubin ≥1.5 up to 3 times upper limit of normal [ULN])
    o Creatinine clearance <45 mL/ min/1.73 m² (by MDRD formula)
    o Comorbidity that, in the Investigator’s opinion, makes the patient unsuitable for intensive chemotherapy and must be documented and approved by the Sponsor before randomization
    3. Criterion numbering modified per Amendment 1
    3.1. De novo or secondary AML;
    4. Criterion modified per Amendment 1
    4.1. Previously untreated AML (except: emergency leukapheresis, hydroxyurea, and /or 1 dose of cytarabine [eg, 1-2g/m^2] during the screening phase to control hyperleukocytosis. Theses treatments mst be discontinued ≥ 24 hours prior to start of study drug). Empiric all trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permited but APL mus be ruled out and ATRA mus be discontinued ≥ 24 hours prior to the start of the study drug;
    5. Criterion numbering modified per Amendment 1
    5.1. Not eligible for an allogeneic hematopoietic stem cell transplantation.
    6. Criterion numbering modified per Amendment 1
    6.1. ECOG Performance Status score of 0, 1 or 2.
    7. Criterion numbering modified per Amendment 1
    7.1. The following clinical laboratory values at screening:
    ● Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 times ULN; for participants with leukemic infiltration of the liver (documented by biopsy or imaging), AST and ALT <5 times ULN is permitted
    ● Total bilirubin ≤ 3 times ULN unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin or in case of liver infiltration by AML (documented by biopsy or imaging) serum total bilirubin <5 times ULN
    ● Creatinine Clearance >30 mL/min (by MDRD formula)
    8. Criterion numbering modified per Amendment 1
    8.1. A woman must be either:
    ● Not of childbearing potential: postmenopausal (>45 years of age with amenorrhea for at least 12 months);
    ● Of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in the clinical study while receiving study tratment and for at least 3 months after the last dose of study treatment.
    A woman of childbearing potential must have a negative highly-sensitive serum (β-human chorionic gonadotropin [β-hCG]) or urine pregnancy test at screening.
    A woman fo childbearing potential must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study treatment and for 3 months after the last dose of study treatment.
    Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) a woman must begin a highly effective method of birth control, as described above.
    9. Criterion modified per Amendment 1
    9.1. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository for at least 3 months after last study treatment.
    ● Must agree to not donate sperm during the study treatment and for 3 months after the last dose of study treatment.
    ● Not plan to father a chld during the study treatment and for 3 months after the last dose os study treatment.
    10. Criterion modified per Amendment
    10.1. Must sign and informed consent form (ICF) indicating that he or she (or their legally acceptable representative) understands the purpose of, and procedures required for, the study and is willing to participate in the study.
    Cada participante potencial debe satisfacer todos los siguientes criterios para ser reclutado en el estudio:
    1. ≥18 años de edad
    2. Criterio modificado por enmienda 1
    2.1. LMA según los criterios de la OMS 2016 y cumpliendo con todos los siguientes criterios que definen a aquellos que "no son candidatos para la quimioterapia intensiva":
    ● ≥75 Años de edad o
    ● <75 años de edad con al menos una de las siguientes comorbilidades:
    o Eastern Cooperative Oncology Group (ECOG) Estado funcional 2
    o Comorbilidad cardíaca severa definida como insuficiencia cardíaca congestiva o fracción de eyección ≤50%
    o Comorbilidad pulmonar severa definida como enfermedad pulmonar documentada con capacidad de difusión pulmonar de monóxido de carbono (DLCO) ≤65% del esperado, o volumen espiratorio forzado en 1 segundo (VEF1) ≤65% del esperado o disnea en reposo que requiere oxígeno
    o Deficiencia hepática moderada definida según los criterios de clasificación de disfunción de órganos del Instituto Nacional del Cáncer (NCI) (bilirrubina total ≥1.5 hasta 3 veces el límite superior de lo normal[ULN]).
    o Aclaramiento de creatinina <45 mL/ min/1.73 m² (por fórmula MDRD)
    o Comorbilidad que, en opinión del Investigador, hace que el paciente no sea apto para quimioterapia intensiva y debe ser documentada y aprobada por el promotor antes de la aleatorización.
    3. Numeración modificada por enmienda 1
    3.1. LMA secundaria o de novo
    4. Criterio modificado por enmienda 1
    4.1. LMA no tratada previamente (excepto: leucoféresis de emergencia, hidroxiurea y/o 1 dosis de citrabina[p. ej., 1-2g/m^2] durante la fase de detección para controlar la hiperleucocitosis. Estos tratamientos deben ser descontinuados ≥ 24 horas antes del inicio del estudio del medicamento). Se permite el tratamiento empírico con ácido transretinoico (ATRA) para la presunta leucemia promielocítica aguda (LPA), pero se debe descartar la LPA y se debe descontinuar el ATRA ≥ 24 horas antes del inicio del tratamiento del estudio;
    5. Numeración modificada por enmienda 1
    5.1. No es elegible para un trasplante alogénico de células madre hematopoyéticas.
    6. Numeración modificada por enmienda 1
    6.1. Puntuación de estado funcional ECOG de 0, 1 o 2.
    7. Numeración modificada por enmienda 1
    7.1. Los siguientes valores de laboratorio clínico en el screening:
    ● Aspartato aminotransferasa (AST) o alanina aminotransferasa (ALT) <3 veces ULN; para los participantes con infiltración leucémica del hígado (documentada por biopsia o imágenes), se permite AST y ALT <5 veces ULN.
    ● Bilirrubina total ≤ 3 veces ULN a menos que el aumento de la bilirrubina se deba al síndrome de Gilbert o de origen no hepático o en caso de infiltración hepática por LMA (documentada mediante biopsia o imágenes) bilirrubina total en suero <5 veces ULN
    ● Aclaramiento de creatinina >30 mL/min (por fórmula MDRD)
    8. Numeración modificada por enmienda 1
    8.1. Una mujer debe ser cualquiera de los dos:
    ● No en edad fértil: postmenopáusica (>45 años de edad con amenorrea durante al menos 12 meses);
    ● En edad fértil y practicar un método altamente efectivo de control de la natalidad consistente con las regulaciones locales con respecto al uso de métodos de control de la natalidad para las participantes que participan en el estudio clínico mientras reciben el tratamiento del estudio y por lo menos 3 meses después de la última dosis del tratamiento del estudio.
    Una mujer en edad fértil debe tener suero negativo altamente sensible (β - gonadotropina coriónica humana[β-hCG]) o prueba de embarazo en orina en el momento del screening.
    Una mujer en edad fértil debe comprometerse a no donar óvulos (óvulos, ovocitos) para fines de reproducción asistida durante el tratamiento del estudio y durante los 3 meses posteriores a la última dosis del tratamiento del estudio.
    Nota: Si el potencial de maternidad cambia después del inicio del estudio (por ejemplo, la mujer que no es heterosexualmente activa se vuelve activa, la mujer premenarcal experimenta la menarquía), la mujer debe comenzar un método altamente efectivo de control de la natalidad, como se describió anteriormente.
    9. Criterio modificado según enmienda 1
    9.1. Un hombre sexualmente activo con una mujer en edad fértil y no se ha sometido a vasectomía debe estar de acuerdo en usar un método anticonceptivo de barrera, por ejemplo, ya sea un condón con espuma/gel/película/crema/supositorio espermicida o una pareja con capuchón oclusivo (diafragma o capuchón cervical/bóveda) con espuma/gel/película/crema/supositorio espermicida por lo menos durante los 3 meses posteriores al último tratamiento del estudio.
    ● Debe aceptar no donar esperma durante el tratamiento del estudio y durante 3 meses después de la última dosis del tratamiento del estudio.
    ● No planee ser padre de un niño durante el tratamiento del estudio y durante 3 meses después de la última dosis del tratamiento del estudio.
    ● Para ver el Criterio de inclusión 10 pueden ir a la página 32 del protocolo
    E.4Principal exclusion criteria
    Any potential participant who meets any of the following criteria will be excluded from participating in the study:
    1. Criterion modified per Amendment 1
    1.1. Acute promyelocytic leukemia
    2. Leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system.
    3. Criterion modified per Amendment 1
    3.1. Use of immune suppressive agents for the past 4 weeks before the first administration of cusatuzumab on Cycle 1 Day 3. For regular use of systemic corticosteroids, participants may only be included if free of systemic corticosteroids for a minimum of 5 days before the first administration of cusatuzumab. Treatment of adrenal insufficiency with physiologic replacement doses of corticosteroids are allowed.
    4. Prior treatment with a hypomethylating agent for treatment of AML or MDS
    5. Criterion modified per Amendment 1
    5.1. Active malignancies (ie, progressing or requiring treatment in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:
    ● Non-melanoma skin cancer treated within the last 24 months that is considered completely cured
    ● Adequately treated breast lobular carcinoma in situ and breast ductal carcinoma in situ
    ● Adequately treated cervical carcinoma in situ without evidence of disease
    ● History of localized breast cancer and receiving antihormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen deprivation therapy
    ● Malignancy that is considered cured with minimal risk of recurrence
    6. Criterion modified per Amendment 1
    6.1. Any active systemic infection
    7. Criterion modified per Amendment 1
    7.1. A history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV at screening
    8. Criterion modified per Amendment 1
    8.1. Active hepatitis B or C infection or other clinically active liver disease
    Seropositive for hepatitis B: defined by a positive test for hepatitis B surface antigen [HBsAg]. Participants with resolved infection (ie, participants who are HBsAg negative with antibodies to total hepatitis B core antigen [anti-HBc] with or without the presence of hepatitis B surface antibody [anti-HBs]) must be screened using real-time polymerase chain reaction (RT-PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are RT-PCR positive will be excluded. Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by RT-PCR.
    Known Hepatitis C infection or positive serologic testing for Hepatitis C (anti-HCV antibody)
    9. New York Heart Association Class IV heart failure or ongoing unstable angina
    10. Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its excipients (ie, mannitol, an excipient of azacitidine).
    11. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or physical limitations that could prevent, limit, or confound the protocol-specified assessments.
    12. Criterion modified per Amendment 1
    12.1. Major surgery, (eg, requiring general anesthesia) within 4 weeks prior to initiation of the study.
    13. Women who are breastfeeding.
    14. Received a live, attenuated vaccine within 4 weeks prior to initiation of study treatment.
    NOTE: Investigators should ensure that all study enrollment (inclusion/exclusion) criteria have been met at screening and prior to the first dose of study intervention. If a participant's clinical status changes (including any available laboratory results or receipt of additional medical records) after screening but before the first dose of study intervention is given such that he or she no longer meets all eligibility criteria, then the participant should be excluded from participation in the study.
    Cualquier participante potencial que cumpla con cualquiera de los siguientes criterios será excluido de participar en el estudio:
    1. Criterio modificado según la enmienda 1
    1.1. Leucemia promielocítica aguda
    2. Afectación leucémica o síntomas clínicos de afectación leucémica del sistema nervioso central.
    3. Criterio modificado según la enmienda 1
    3.1. Uso de agentes inmunosupresores durante las últimas 4 semanas antes de la primera administración de cusatuzumab en el ciclo 1 Día 3. Para el uso regular de corticosteroides sistémicos, los participantes sólo pueden ser incluidos si están libres de corticosteroides sistémicos durante un mínimo de 5 días antes de la primera administración de cusatuzumab. Se permite el tratamiento de la insuficiencia suprarrenal con dosis fisiológicas de reemplazo de corticosteroides.
    4. Tratamiento previo con un agente hipometilante para el tratamiento de la LMA o los SMD
    5. Criterio modificado según la enmienda 1
    5.1. Malignidades activas (es decir, que progresan o requieren tratamiento en los últimos 24 meses) que no sean la enfermedad que se está tratando en estudio. Las únicas excepciones permitidas son:
    ● Cáncer de piel no melanoma tratado en los últimos 24 meses que se considera completamente curado
    ● Carcinoma lobular de mama tratado adecuadamente in situ y carcinoma ductal de mama in situ
    ● Carcinoma de cuello uterino tratado adecuadamente in situ sin evidencia de enfermedad
    ● Antecedentes de cáncer de mama localizado y recibiendo agentes antihormonales, o antecedentes de cáncer de próstata localizado (N0M0) y recibiendo terapia de privación de andrógenos.
    ● Malignidad que se considera curada con un riesgo mínimo de recurrencia
    6. Criterio modificado según la enmienda 1
    6.1. Cualquier infección sistémica activa
    7. Criterio modificado según la enmienda 1
    7.1. Antecedentes de anticuerpos contra el virus de la inmunodeficiencia humana (VIH) positivos o pruebas positivas para el VIH en el momento de la prueba de detección
    8. Criterio modificado según la enmienda 1
    8.1. Infección activa por hepatitis B o C u otra enfermedad hepática clínicamente activa
    Seropositivo para hepatitis B: definido por una prueba positiva para el antígeno de superficie de la hepatitis B[HBsAg]. Los participantes con infección resuelta (es decir, los participantes que son negativos al HBsAg con anticuerpos contra el antígeno central de la hepatitis B total[anti-HBc] con o sin la presencia de anticuerpos de superficie de la hepatitis B[anti-HBBs]) deben ser examinados usando la medición en tiempo real de los niveles de ADN del virus de la hepatitis B (VHB) por reacción en cadena de la polimerasa (RT-PCR). Se excluirá a los que sean positivos a la RT-PCR. Los participantes con hallazgos serológicos que sugieran la vacunación contra el VHB (positividad anti-HBs como único marcador serológico) Y un historial conocido de vacunación previa contra el VHB, no necesitan ser sometidos a pruebas de ADN del VHB mediante RT-PCR.
    Infección conocida de hepatitis C o prueba serológica positiva para hepatitis C (anticuerpo anti-HCV)
    9. New York Heart Association Insuficiencia cardíaca de clase IV o angina inestable continua
    10. Alergias conocidas, hipersensibilidad o intolerancia al cusatuzumab o azacitidina o sus excipientes (es decir, manitol, un excipiente de azacitidina).
    11. Cualquier condición para la cual, en la opinión del investigador, la participación no sería en el mejor interés del participante (p.e., comprometer el bienestar) o limitaciones físicas que podrían prevenir, limitar o confundir las evaluaciones especificadas en el protocolo.
    12. Criterio modificado según la enmienda 1
    12.1. Cirugía mayor, (por ejemplo, que requiere anestesia general) dentro de las 4 semanas previas al inicio del estudio.
    13. Mujeres que están amamantando.
    14. Recibió una vacuna viva atenuada dentro de las 4 semanas anteriores al inicio del tratamiento del estudio.
    NOTA: Los investigadores deben asegurarse de que se hayan cumplido todos los criterios de reclutamiento en el estudio (inclusión/exclusión) en el momento del screening y antes de la primera dosis de intervención del estudio. Si el estado clínico de un participante cambia (incluidos los resultados de laboratorio disponibles o la recepción de historias clínicas adicionales) después del screening, pero antes de que se administre la primera dosis de intervención del estudio de tal manera que ya no cumpla con todos los criterios de elegibilidad, entonces el participante debe ser excluido de participar en el estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Complete response (CR) rate per ELN 2017 (Dohner 2017)
    Índice de respuesta completa (CR) según ELN 2017 (Dohner 2017)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Every other cycle, starting at Cycle 1, (between Day 21 up to and including Day 1 of the next cycle)
    Cada dos ciclos, comenzando en el Ciclo 1, (entre el Día 21 hasta el Día 1 del siguiente ciclo inclusive)
    E.5.2Secondary end point(s)
    1. Rate of CRh
    2. Rate of CR + CRh
    3. Rate of CRi
    4. Overall response rate (ORR) = Rate of CR+ CRh+ CRi
    5. Rate of CR without MRD
    6. Rate of MRD negativity among participants achieving CR, CRh, CRi, or MLFS ; defined as less than 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3)
    7. Time to response, defined as time from randomization in Part 1 or enrollment in Part 2 to achieving the first response of CR, CRh, or CRi; duration of response, defined as time from achieving the first response of CR, CRh, or CRi to disease relapse or death from any cause.
    8. Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug + 30 days.
    9. Safety profile of Adverse Events (AE) and Serious Adverse Events (SAE)
    10. Pharmacokinetics
    11. Immunogenicity / anti-drug antibody testing
    1. Tasa de RCh
    2. Tasa de RC + RCh
    3. Tasa de RCi
    4. Tasa de respuesta global (ORR) = Tasa de RC+ RCh+ RCi
    5. Tasa de RC sin MRD
    6. Tasa de negatividad de MRD entre los participantes que logran RC, RCh, RCi, o MLFS; definida como menos de 1 explosión o célula madre leucémica en 1,000 leucocitos (nivel de MRD <10^-3)
    7. Tiempo de respuesta, definido como el tiempo transcurrido desde la aleatorización en la Parte 1 o el reclutamiento en la Parte 2 hasta alcanzar la primera respuesta de RC, RCh o RCi; duración de la respuesta, definida como el tiempo transcurrido desde la consecucion de la primera respuesta de RC, RCh o RCi hasta la recaída de la enfermedad o la muerte por cualquier causa.
    8. La independencia de la transfusión (glóbulos rojos o plaquetas) se define como un período de al menos 56 días consecutivos sin transfusión entre la primera dosis del fármaco en estudio y la última dosis del fármaco en estudio + 30 días.
    9. Perfil de seguridad de los Eventos Adversos (EA) y de los Eventos Adversos Graves (EAE)
    10. Farmacocinética
    11. Pruebas de inmunogenicidad / anticuerpos antidroga1. Tasa de RCh
    10. Farmacocinética
    11. Pruebas de inmunogenicidad / anticuerpos anti medicacion
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 to 7.Every other cycle, starting at Cycle 1, (between Day 21 up to and including Day 1 of the next cycle) until CR or progressive disease and then every 4th cycle until relapse. Once CR without MRD is achieved, a repeat bone marrow examination should be performed at least 4 weeks later.
    8. At least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study + 30 days
    9. Throughout the study until followup
    10. Cycle (C) 1 Day (D) 3, C1D4, C1D7, C1D10, C1D17, C2D3, C2D17, C3D3 and C4D3, C3D17 and C4D17, C3D21 to C4D1, C5D3, C5D21 to C6D1, Odd cycles ≥C7D3 and EOT (end of treatment) up to 22 Oct 2021
    11. C1D3, C1D17, C2D3, C2D17, C3D3 and C4D3, C5D3, Odd cycles ≥C7D3 and EOT
    1 a 7.Cada dos ciclos, comenzando en el Ciclo 1, (entre el Día 21 hasta el Día 1 del siguiente ciclo inclusive) hasta la RC o progresión de la enfermedad y luego cada 4 ciclos hasta la recaída. Una vez que se logra la RC sin EMR, se debe repetir el examen de la médula ósea por lo menos 4 semanas después.
    8. Al menos 56 días consecutivos sin transfusión entre la primera dosis del fármaco en estudio y la última dosis del estudio + 30 días
    9. A lo largo del estudio hasta el seguimiento
    10. Ciclo (C) 1 Día (D) 3, C1D4, C1D7, C1D10, C1D17, C2D3, C2D17, C3D3 y C4D3, C3D17 y C4D17, C3D21 a C4D1, C5D3, C5D21 a C6D1, Ciclos impares ≥C7D3 y EOT (fin de tratamiento) hasta el 22 Oct 2021.
    11. C1D3, C1D17, C2D3, C2D17, C3D3 y C4D3, C5D3, Ciclos impares ≥C7D3 y EOT
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability and Biomarker evaluations, Cytogenetics/ Mutational analysis, Immunogenicity and Patient-reported outcomes
    Evaluaciones de tolerabilidad y Biomarcadores, análisis citogenético y de mutación, inmunogenicidad y resultados comunicados por el paciente
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA28
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Switzerland
    Australia
    Brazil
    Israel
    Russian Federation
    United States
    France
    Italy
    Spain
    Türkiye
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study will be reached when all subjects have completed or discontinued study treatment
    El fin del estudio se alcanzará cuando todos los sujetos hayan completado o suspendido el tratamiento de estudio
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 8
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 95
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Refer to the protocol and informed consent form
    Consulte el protocolo y el formulario de consentimiento informado
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 39
    F.4.2.2In the whole clinical trial 103
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who are continuing to derive benefit from treatment with cusatuzumab, azacitidine or both agents as assessed by their investigator at the end of the study may continue to receive these medications.
    Los participantes que continúan obteniendo beneficios del tratamiento con cusatuzumab, azacitidina o ambos agentes según lo evaluado por su investigador al final del estudio pueden continuar recibiendo estos medicamentos.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-08-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-06-25
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:43:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA